News Avalyn seeks $300m from its IPO Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.
News Teva makes its first M&A play in years, buying Emalex Teva has made its first pipeline-building acquisition in almost a decade, buying Tourette syndrome drug developer Emalex for up to $900m.
News AZ will invest £300m in UK, says PM Keir Starmer AstraZeneca has delivered a much-needed boost to the UK government alongside a strong set of first-quarter results.
News Amgen, AZ will pilot FDA's real-time clinical trial plan The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.
News AI start-up Profluent nabs Lilly as first big pharma partner AI start-up Profluent has signed a major alliance with pharma group Eli Lilly, worth up to $2.25bn, that will focus on gene-editing therapies.
News Boehringer/Zealand dual-acting drug causes 16.6% weight loss Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.
News Parexel buys Vitrana to boost patient safety toolkit Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
